The acting director of the National Institute of Allergy and Infectious Diseases resigned ahead of a Senate hearing Thursday, adding to leadership turnover across U.S. health agencies during ongoing Ebola and hantavirus response efforts. NIH Director Jay Bhattacharya confirmed the institute is shifting priorities under the Trump administration as lawmakers raised concerns about staffing vacancies and delayed research funding.
- Jeffery Taubenberger stepped down as acting head of NIAID after serving since April 2025.
- Senators Tammy Baldwin and Patty Murray said multiple senior NIAID officials have recently departed or been reassigned.
- NIH Director Jay Bhattacharya said the administration is redirecting NIAID away from civilian biodefense and toward infectious diseases, allergy and immunology.
- NIAID manages a budget exceeding $6.5 billion and played major roles in prior COVID-19 and Ebola responses.
- Lawmakers raised concerns over leadership gaps during the Ebola outbreak in the Democratic Republic of Congo and ongoing hantavirus monitoring efforts.
- The White House’s proposed 2027 NIH budget would reduce agency funding by roughly $5 billion.
Relevant Companies
- Moderna ($MRNA) – Federal infectious disease priorities and NIH funding decisions can impact vaccine and outbreak-response partnerships.
- Pfizer ($PFE) – NIH and public health policy shifts may affect infectious disease research collaboration and funding.
- Gilead Sciences ($GILD) – The company has exposure to antiviral and infectious disease treatment development tied to federal health initiatives.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
